About Polaris Quantum Biotech
Polaris Quantum Biotech (PolarisQB) is a computational drug discovery company that leverages quantum computing technology to accelerate the identification of novel drug candidates. The company's proprietary Quantum-Aided Drug Design (QuADD) platform uses quantum annealing and quantum-inspired algorithms to solve ultra-large scale optimization problems in molecular design that are too complex for traditional computers. PolarisQB's approach enables exploration of chemical spaces exceeding 10^30 molecules—more than 20 orders of magnitude larger than conventional screening methods—in just hours rather than weeks or months. The platform performs multi-objective optimization at unprecedented scale and speed, applicable to any protein target without requiring training data. PolarisQB serves pharmaceutical companies, biotech firms, agricultural companies, and contract research organizations (CROs), offering solutions ranging from rapid lead generation to collaborative joint development programs. The company has demonstrated significant advantages over traditional computer-aided drug design (CADD), delivering stronger binding candidates with greater diversity and more drug-like properties in dramatically shorter timeframes. Based in Durham, North Carolina, PolarisQB partners with organizations across drug discovery, longevity research, and women's health to accelerate the path from target identification to viable drug candidates.
Who It Serves
Milestones & Awards
Recent Milestones
Selected as 2026 winner of Cleveland Clinic Quantum Innovation Catalyzer Program (April 2026); Announced exclusive representation agreement with PTG for Greater China and Southeast Asia (June 2026); Demonstrated advances in drug safety prediction with quantum-inspired AI (April 2026); Free trials of QuADD platform now available
Awards & Recognition
2026 winner of the Cleveland Clinic Quantum Innovation Catalyzer Program
Key Partnerships
Company Details
- Headquarters
- Durham, NC, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.